DDInter849 DDInter1676
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Guselkumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Guselkumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Guselkumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Guselkumab may lead to a major life threatening interaction when taken with Upadacitinib